Focal adhesion kinase market is anticipated to grow at a significant CAGR during the forecast period. The non-receptor tyrosine kinase focal adhesion kinase (FAK) provides signaling and scaffolding functions at integrin adhesion sites. It is involved in the management of the turnover of these adhesion sites, which is critical for cell migration control. FAK has been connected to cell defense against anoikis (suspension-induced cell death). FAK’s ability to sequester receptor-interacting protein (RIP) from the death-receptor machinery can be linked to its anti-apoptotic action.
FAK is a non-receptor tyrosine kinase that initiates signal transduction pathways at integrin-mediated cell adhesion sites and through growth factor receptors. Survival, proliferation, migration, and invasion are all mechanisms involved in the formation and progression of cancer, and FAK is a crucial regulator of these activities. On a biochemical and functional level, FAK is connected to oncogenes. Furthermore, FAK overexpression and/or enhanced activity are found in a wide range of human malignancies, suggesting that FAK plays a role in carcinogenesis. FAK can be considered a possible target in the development of anti-cancer therapies owing to its crucial role in a variety of events associated with carcinogenesis, metastasis, and survival signaling. As a result, FAK inhibitors that are specific must be created. Combining these selective FAK inhibitors with cytotoxic drugs could be an extremely effective anti-cancer treatment. Therefore, the rising prevalence of cancer is driving the growth of the global focal adhesion kinase market during the forecast period. According to the Globocan 2020, there were nearly 19.3 million new cancer cases identified globally, with about 9.9 million cancer-related mortalities. Furthermore, the International Agency for Research on Cancer (IARC) predicts that by 2040, the global burden of cancer would be increased to 27.5 million new cancer cases and 16.3 million mortalities.
To Request a Sample of our Report on Focal Adhesion Kinase Market: https://www.omrglobal.com/request-sample/focal-adhesion-kinase-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, and Teva Pharmaceutical Industries Ltd. among others.
Focal Adhesion Kinase Market Report by Segment
By Type
- VS-4718
- CT-707
- GSK-2256098
- Cilengitide
- BI-853520
- Others
By Application
- Clinic
- Hospital
- Others
A full Report of Focal Adhesion Kinase Market is Available @ https://www.omrglobal.com/industry-reports/focal-adhesion-kinase-market
Focal Adhesion Kinase Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
